The looming threat of antibiotic resistance-predicted to cause over 10 million deaths globally each year by 2050-may have an unlikely ally: inhaled nitric oxide. Researchers are exploring whether this gas, already a life-saver for newborns with heart defects, can also combat stubborn, drug-resistant bacteria like Pseudomonas aeruginosa, responsible for roughly one-fifth of hospital-acquired pneumonia cases and often leading to severe illness.
A New Weapon Against superbugs?
Could a common therapeutic gas offer a novel approach to fighting antibiotic-resistant infections?
- Nitric oxide, traditionally used for newborns with congenital heart disease, is showing promise as an antimicrobial agent.
- Preclinical studies in pigs demonstrated reduced bacterial burden and improved lung function with high-dose inhaled nitric oxide (iNO) treatment.
- early human studies indicate that high-dose iNO is safe and feasible, paving the way for larger clinical trials.
- Researchers emphasize that this is a translational foundation, not a ready-made clinical solution, and rigorous testing is still needed.
Nitric oxide is no stranger to the medical world. for nearly three decades, it has been a critical therapy for hundreds of thousands of newborns struggling with congenital heart disease. Now, investigators from the same laboratory that pioneered its use in infants are investigating its potential to fight bacterial infections.
thier recent work, published in Science Translational Medicine (DOI: 10.1126/scitranslmed.ady2646, www.science.org/doi/10.1126/scitranslmed.ady2646), suggests that high-dose inhaled nitric oxide (iNO) exhibits antimicrobial activity in laboratory models. The findings also indicate that iNO is safe and can be administered to humans, supporting further investigation into its clinical effectiveness.
Journal data: Science Translational Medicine
